Autodesk Stock Forecast: Prediction Missed, but Large Potential to Grow

Kun
The article was written by Kun Qiu, a Financial Analyst at I Know First.

Summary

  • Autodesk’s strategic shift from traditional software provider to innovation company was proven effective since the company’s revenue was steadily increasing.
  • Autodesk failed to reach the consensus EPS anticipation, but the non-GAAP earnings of fiscal 2020 first quarter per share $0.45 is far beyond $0.06 for the same quarter last year.
  • Autodesk’s stock price still has a large potential to grow if Autodesk could maintain its leading role in CAD industry and apply its core strategy successfully.

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

YELP Stock Forecast: Is Now a Good Time to Buy?

 

 

This article was written by Isabelle Tao, a Financial Analyst at I Know First.

YELP Stock Forecast

“On the internet, competition is one click away” - Jeremy Stoppelman, YELP CEO

Highlights:

  • Strong Q2 performance
  • Ramping up battle against Google’s monopoly
  • Growing revenue from changing advertisement business model
  • I Know First’s Algorithm is Bullish for YELP in the Long Run

(Source: Wikimedia Commons)

premiumRead The Full Premium Article

Subscribe to our exclusive content in the PREMIUM section here

Winning Stock Forecast: Shorting ALGN Stock Returns 26.44% in 14 Days

Winning Stock Forecast: Shorting ALGN Stock Returns 26.44% in 14 Days

Align Technology Inc (ALGN)

Align Technology is a global medical device company with industry-leading innovative products such as Invisalign clear aligners, iTero Intraoral scanners, and OrthoCAD digital services that help dental professionals achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients.

Source: aligntech.com

ALGN saw a drop of -26.44% in its stock over the past 14 days. Align Technology is a manufacturer of 3D digital scanners and clear aligners used in orthodontics. The Company offers a system that corrects the misalignment using a series of clear and removable appliances that move teeth to a desired final position. However, many of the company’s patents have expired, as of December 17, and it is now facing fierce competition in the market. Although they are still the market leaders this has not provided investors with the confidence that ALGN is a company with a long-term product.

On October 24, 2018, Align and management announced the Company’s 3Q 2018 earnings. They reported clear-aligner sales of $427.1 million, up 25% over the prior-year period but a sequential decline of 1.4%. This drop stemmed primarily from lower average selling prices (“ASPs”) in the U.S. and internationally. Align and management blamed the lower ASPs in part on promotional discounts. This news drove the price of Align shares down as much as $87.71, or about 30%, during intraday trading on October 25, 2018. “We’re focused on investors’ losses and on the extent to which management’s statements concerning competition, sales, and promotions were misleading,” said Hagens Berman partner Reed Kathrein LLP, the Law firm representing ALGN.

This chart below shows the algorithmic forecast made on these top ten long and short options and the results of the forecast. As seen ALGN was included in the top ten short options.

Current I Know First subscribers received this bearish forecast  for  ALGN on October 12th

 To subscribe today click here.

 Algorithmic traders utilise these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast.

About

Align Technology, Inc. (ALGN) incorporated on April 3, 1997, designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment. The Clear Aligner segment consists of its Invisalign System, which includes Invisalign Full, Teen and Assist (Comprehensive Products), Express/Lite (Non-Comprehensive Products) and Vivera Retainers, along with its training and ancillary products for treating malocclusion (Non-Case). The Scanner segment consists of intra-oral scanning systems and other services available with the intra-oral scanners that provide digital alternatives to the traditional cast models. The Scanner segment includes its iTero scanner and OrthoCAD services. iTero scanner is used by dental professionals, and labs and services for restorative and orthodontic digital procedures, as well as Invisalign digital impression submission

 

 

Winning Stock Forecast: Biopharma Company Amarin Corporation PLC (NASDAQ: AMRN) Brings 16.01 % In 7 Days

AMRN Winning Stock Forecast

Source: kisspng.com

This week biopharma company AMRN saw a 16.01 % jump, being the 7 day forecast’s biggest earner, as the I Know First algorithm predicted. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid. Heart Disease is still the leading factor for deaths in the USA and following recent patient trials Vascepa users are 25% less likely to suffer from a cardiac arrest. These impressive results thrust Vascepa as the industry leader drug for those suffering with high cholesterol.

Amarin Corporation lost $92 million this year because sales of Vascepa just haven’t kept pace with operating expenses. However, they are putting huge investment into turning their drug Vascepa into a ‘blockbuster.’ Many critics are often sceptical about such investment but in this case it appears that Amarin may be an exception. With a positive trail the market reaction has seen Amarin as a company with long term potential and investors will continue to support this drug.

Source: maxpixel.net

Current I Know First subscribers received a bullish AMRN forecast on October 11th. With a strong signal of 31.89 for the week-long time frame.

Traders and investors utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers on October 11th.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.

About

Amarin Corporation plc, incorporated on March 1, 1989, is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers